cAMP Analogs Induce p53-independent p21 Expression through Sp1-responsive Promoter Activation and p300-associated Epigenetic Regulation in PC-3 Human Prostate Cancer Cells.
4 affiliations
- 1Anti-Aging Research Center, Dong-Eui University Busan Korea.
- 2Department of Biochemistry, Dong-Eui University College of Korean Medicine Busan Korea.
- 3Department of Food Science & Biotechnology, College of Engineering, Kyungsung University Busan Korea.
- 4Department of Dental Hygiene, College of Health Science, Youngsan University Yangsan Korea.
Abstract
cAMP signaling regulates cell proliferation and survival in various cancers, but the molecular mechanisms underlying its antiproliferative effects in androgen-independent prostate cancer are not fully understood. This study investigated the growth-inhibitory effects of cAMP signaling and its regulatory mechanisms in p53-deficient PC-3 human prostate cancer cells using cAMP analogs, 8-bromo-cAMP and dibutyryl-cAMP. Both cAMP analogs significantly suppressed PC-3 cell proliferation in a time-dependent manner, inducing G1 cell cycle arrest and apoptotic cell death. cAMP treatment reduced cyclin-dependent kinase (Cdk) activity and retinoblastoma protein (pRB) phosphorylation, which enhanced pRB-E2F complex formation and repressed E2F-dependent signaling. cAMP analogs significantly upregulated p21 expression at both transcriptional and translational levels, independently of p53. The increased binding of p21 to Cdk2 and Cdk4 supported its role in inhibiting cyclin-Cdk. Promoter analyses showed that cAMP transcriptionally activated the p21 promoter via Sp1-responsive elements. While the transcription co-activator p300, possessing histone acetyltransferase activity, enhanced cAMP-induced p21 promoter activity, dominant-negative p300 attenuated this effect. Furthermore, trichostatin A, a histone deacetylase inhibitor, potentiated p21 promoter activation, indicating that histone acetylation is crucial for cAMP-mediated p21 transcription. In conclusion, cAMP analogs suppress PC-3 cell proliferation through a mechanism involving p53-independent p21 induction, together with Sp1-responsive promoter activation and p300-associated epigenetic regulation.
Related
- Epigenetic Silencing of ZNF471 Contributes to Osimertinib Resistance in Lung Adenocarcinoma: β-Hydroxybutyrate Associates with ZNF471 Re-Expression and Reduced Resistance-Associated Phenotypes
- Compensatory activation of PI3K/AKT signaling and apoptosis-associated protein expression in pulmonary hypertension-induced right ventricular dysfunction
- RNF152 promoter methylation and gene expression in oral premalignant lesions and oral squamous cell carcinoma: implications for epigenetic biomarker development
- TET2-driven activation of AGO2 links epigenetic remodeling to myeloid commitment and leukemia
- LIF and let die: Generation, mechanistical and structural characterization of bispecific antibodies triggering leukemia inhibitory factor (LIF) receptor activation independent of the cytokine LIF
BibTeX
@article{hwangbo2026camp,
title = {{cAMP Analogs Induce p53-independent p21 Expression through Sp1-responsive Promoter Activation and p300-associated Epigenetic Regulation in PC-3 Human Prostate Cancer Cells.}},
author = {Hyun Hwangbo and Sung Ok Kim and Soon-Jeong Jeong and Su Hyun Hong and Yung Hyun Choi},
journal = {Journal of cancer prevention},
year = {2026},
month = oct,
doi = {10.15430/jcp.26.031},
url = {https://europepmc.org/article/MED/42996564},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - cAMP Analogs Induce p53-independent p21 Expression through Sp1-responsive Promoter Activation and p300-associated Epigenetic Regulation in PC-3 Human Prostate Cancer Cells.
AU - Hyun Hwangbo
AU - Sung Ok Kim
AU - Soon-Jeong Jeong
AU - Su Hyun Hong
AU - Yung Hyun Choi
PY - 2026
DA - 2026/10/01
JO - Journal of cancer prevention
DO - 10.15430/jcp.26.031
UR - https://europepmc.org/article/MED/42996564
AB - cAMP signaling regulates cell proliferation and survival in various cancers, but the molecular mechanisms underlying its antiproliferative effects in androgen-independent prostate cancer are not fully understood. This study investigated the growth-inhibitory effects of cAMP signaling and its regulatory mechanisms in p53-deficient PC-3 human prostate cancer cells using cAMP analogs, 8-bromo-cAMP and dibutyryl-cAMP. Both cAMP analogs significantly suppressed PC-3 cell proliferation in a time-dependent manner, inducing G1 cell cycle arrest and apoptotic cell death. cAMP treatment reduced cyclin-dependent kinase (Cdk) activity and retinoblastoma protein (pRB) phosphorylation, which enhanced pRB-E2F complex formation and repressed E2F-dependent signaling. cAMP analogs significantly upregulated p21 expression at both transcriptional and translational levels, independently of p53. The increased binding of p21 to Cdk2 and Cdk4 supported its role in inhibiting cyclin-Cdk. Promoter analyses showed that cAMP transcriptionally activated the p21 promoter via Sp1-responsive elements. While the transcription co-activator p300, possessing histone acetyltransferase activity, enhanced cAMP-induced p21 promoter activity, dominant-negative p300 attenuated this effect. Furthermore, trichostatin A, a histone deacetylase inhibitor, potentiated p21 promoter activation, indicating that histone acetylation is crucial for cAMP-mediated p21 transcription. In conclusion, cAMP analogs suppress PC-3 cell proliferation through a mechanism involving p53-independent p21 induction, together with Sp1-responsive promoter activation and p300-associated epigenetic regulation.
SN - 2288-3649
SN - 2288-3657
ER -